28 unchanged sentences
In our opinion, the Company maintained, in all material respects, effective internal control over financial reporting as of December 31, 2024, based on criteria established in Internal Control — Integrated Framework (2013) issued by COSO.
−Removed: We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the financial statements as of and for the year ended December 31, 2023, of the Company and our report dated February 27, 2024, expressed an unqualified opinion on those financial statements.
+Added: We have also audited, in accordance with the standards of the Public Company Accounting Oversight Board (United States) (PCAOB), the financial statements as of and for the year ended December 31, 2024, of the Company and our report dated March 3, 2025, expressed an unqualified opinion on those financial statements.
Basis for Opinion
17 unchanged sentences
San Francisco, California
−Removed: February 27, 2024
+Added: March 3, 2025
Other Information.
1 unchanged sentence
Other than those listed below, none of the Company’s directors or officers adopted , modified or terminated a Rule 10b5-1 trading arrangement or a non-Rule 10b5-1 trading arrangement during the three months ended December 31, 2024, as such terms are defined under Item 408(a) of Regulation S-K.
−Removed: On October 4, 2023 , Mike Ouimette , our General Counsel , entered into a trading plan, or the Ouimette 10b5-1 Sales Plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: Under the Ouimette 10b5-1 Sales Plan, an aggregate of 57,074 shares of the Company’s common stock and up to 33% of the net shares Mr.
−Removed: Ouimette may receive from the vesting of certain outstanding RSU and PSU awards from time to time between January 16, 2024 and July 1, 2024 (the “Ouimette Authorized Shares”) may be sold.
−Removed: Due to vesting conditions of the awards and the number of shares withheld for taxes, to be determined only on the vesting date and market conditions, the number of shares actually sold under the Ouimette 10b5-1 Sales Plan may be less than the maximum number of shares that can be sold.
−Removed: The Ouimette 10b5-1 Sales Plan, which was entered into during an open trading window under the Company’s insider trading policy, will be in effect until the earlier of (1) December 31, 2024, or (2) the date on which all Ouimette Authorized Shares have been sold under the Ouimette 10b5-1 Sales Plan.
−Removed: On December 7, 2023 , Eric Lefebvre , our Chief Medical Officer , entered into a trading plan, or the Lefebvre 10b5-1 Sales Plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: Under the Lefebvre 10b5-1 Sales Plan, an aggregate of 111,781 shares of the Company’s common stock may be sold (such aggregate amount, which may be reduced by any shares sold prior pursuant to a prior trading plan adopted by Dr.
+Added: On November 27, 2024 , Eric Lefebvre , our Chief Medical Officer , entered into a trading plan, or the Lefebvre 10b5-1 Sales Plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
+Added: Under the Lefebvre 10b5-1 Sales Plan, which goes into effect on March 10, 2025, an aggregate of 111,781 shares of the Company’s common stock may be sold (such aggregate amount, which may be reduced by any shares sold prior pursuant to a prior trading plan adopted by Dr.
Lefebvre on December 7, 2023 and prior to initiation of sales pursuant to the Lefebvre 10b5-1 Sales Plan, the “Lefebvre Authorized Shares”).
The Lefebvre 10b5-1 Sales Plan, which was entered into during an open trading window under the Company’s insider trading policy, will be in effect until the earlier of (1) March 7, 2026 , or (2) the date on which all Lefebvre Authorized Shares have been sold under the Lefebvre 10b5-1 Sales Plan.
−Removed: On December 13, 2023 , Bernard Coulie , our Chief Executive Officer , entered into a trading plan, or the Coulie 10b5-1 Sales Plan, intended to satisfy the affirmative defense of Rule 10b5-1(c) under the Exchange Act.
−Removed: Under the Coulie 10b5-1 Sales Plan, an aggregate of 80,000 shares of the Company’s common stock may be sold.
−Removed: The Coulie 10b5-1 Sales Plan, which was entered into during an open trading window under the Company’s insider trading policy, will be in effect until the earlier of (1) December 31, 2024, or (2) the date on which the maximum number of shares of the Company’s common stock have been sold under the Coulie 10b5-1 Sales Plan.
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections.
6 unchanged sentences
If we make any substantive amendments to our Code of Conduct or grant any of our directors or executive officers any waiver, including any implicit waiver, from a provision of our Code of Conduct, we will disclose the nature of the amendment or waiver on our website or in a Current Report on Form 8-K.
+Added: We have an insider trading policy governing the purchase, sale and other dispositions of our securities that applies to all personnel of Pliant and its subsidiaries, including directors, officers, employees and other covered persons.
+Added: We believe that our insider trading policy is reasonably designed to promote compliance with insider trading laws, rules and regulations, as well as applicable listing standards.
+Added: A copy of our insider trading policy is filed as Exhibit 19.1 to this report.
Executive Compensation.
18 unchanged sentences
10-Q 001-39303 3.1 August 11, 2020
−Removed: Second Amended and Restated Bylaws of the Registrant, as currently in effect.
+Added: Third Amended and Restated Bylaws of the Registrant, as currently in effect.
8-K 001-39303 3.1 September 24, 2024
27 unchanged sentences
S-1 333-238146 10.13 May 11, 2020
−Removed: Office Lease, by and between the Registrant and 260 Littlefield Avenue South San Francisco, California 94080, dated February 6, 2018.
−Removed: S-1 333-238146 10.14 May 11, 2020
2022 Inducement Plan dated September 14, 2022.
−Removed: 10-K 001-39303 10.17 March 9, 2023
+Added: Amended and Restated Loan and Security Agreement, by and among the Registrant, the lenders from time to time party thereto and Oxford Finance LLC, dated March 11, 2024.
+Added: 10-Q 001-39303 10.3 May 6, 2024
+Added: Amended and Restated Non-Employee Director Compensation Policy
+Added: 10-K 001-39303 10.17 February 27, 2024
Incorporated by Reference
1 unchanged sentence
Exhibit Filing
−Removed: Loan and Security Agreement, by and between Registrant and Oxford Finance LLC, dated May 4, 2022.
−Removed: 8-K 001-39303 10.1 May 5, 2022
−Removed: First Amendment to Loan and Security Agreement, by and between Registrant and Oxford Finance LLC, dated October 4, 2022.
−Removed: 10-K 001-39303 10.17 March 9, 2023
−Removed: Amended and Restated Non-Employee Director Compensation Policy
Offer Letter, by and between the Registrant and Lily Cheung, dated December 21, 2022.
2 unchanged sentences
8-K 001-39303 10.1 October 23, 2023
−Removed: Termination Agreement by and between the Registrant and Healthpeak OP, LLC, dated September 28, 2023.
−Removed: 8-K 001-39303 10.2 October 23, 2023
+Added: Amended and Restated Non-Employee Director Compensation Policy
+Added: Insider Trading
Consent of Independent Registered Public Accounting Firm
4 unchanged sentences
Clawback Policy
+Added: 10-K 001-39303 97 February 27, 2024
101.INS XBRL Instance Document X
7 unchanged sentences
# Represents management compensation plan, contract or arrangement.
−Removed: † Portions of this exhibit have been omitted pursuant to Item 601(b) of Regulation S-K.
Form 10-K Summary
Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, thereunto duly authorized .
−Removed: February 27, 2024
+Added: March 3, 2025
PLIANT THERAPEUTICS, INC.
10 unchanged sentences
Name Title Date
−Removed: /s/ Bernard Coulie President, Chief Executive Officer and Director February 27, 2024
+Added: /s/ Bernard Coulie President, Chief Executive Officer and Director March 3, 2025
Bernard Coulie, M.D., Ph.D.
Principal Executive Officer
−Removed: /s/ Keith Cummings Chief Financial Officer February 27, 2024
+Added: /s/ Keith Cummings Chief Financial Officer March 3, 2025
Keith Cummings, M.D., M.B.A.
Principal Financial Officer
−Removed: /s/ Hoyoung Huh Chairman of the Board, Director February 27, 2024
+Added: /s/ Hoyoung Huh Chairman of the Board, Director March 3, 2025
Hoyoung Huh, M.D., Ph.D.
−Removed: /s/ Suzanne Bruhn Director February 27, 2024
+Added: /s/ Suzanne Bruhn Director March 3, 2025
Suzanne Bruhn, Ph.D.
−Removed: /s/ Darren Cline Director February 27, 2024
−Removed: /s/ David Pyott Director February 27, 2024
−Removed: /s/ Gayle Crowell Director February 27, 2024
+Added: /s/ Darren Cline Director March 3, 2025
+Added: Darren Cline, M.B.A.
+Added: /s/ David Pyott Director March 3, 2025
+Added: David Pyott, M.A, M.B.A.
+Added: /s/ Gayle Crowell Director March 3, 2025
Gayle Crowell
−Removed: /s/ John Curnutte Director February 27, 2024
−Removed: John Curnutte, M.D.
−Removed: /s/ Katharine Knobil Director February 27, 2024
+Added: /s/ John Curnutte Director March 3, 2025
+Added: John Curnutte, M.D., Ph.D
+Added: /s/ Katharine Knobil Director March 3, 2025
Katharine Knobil, M.D.
−Removed: /s/ Thomas McCourt Director February 27, 2024
+Added: /s/ Thomas McCourt Director March 3, 2025
Thomas McCourt
−Removed: /s/ Smital Shah Director February 27, 2024
+Added: /s/Steve Krognes Director March 3, 2025
+Added: Steve Krognes, M.B.A.
+Added: /s/ Smital Shah Director March 3, 2025
+Added: Smital Shah, M.B.A.
Compared sentence by sentence after normalising whitespace, quotation marks, case and digits, so re-formatting and restated figures do not read as changed language. Wording changes appear as one removal and one addition. The current filing and the prior one are authoritative.